icosapent ethyl (IPE)

DRUG3 trials

Sponsors

VA Office of Research and Development, Estudios Clínicos Latino América, China National Center for Cardiovascular Diseases

Conditions

Alzheimer's DiseaseCOVID19Coronary Artery DiseaseCoronary AtherosclerosisHyperlipidaemiaHypertriglyceridaemia

Phase 2

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

CompletedNCT02719327

VA Office of Research and DevelopmentAlzheimer's Disease

Start: 2017-06-08End: 2023-09-29Updated: 2024-11-26

Phase 3

PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial

CompletedNCT04460651

Estudios Clínicos Latino AméricaCOVID19

Start: 2020-08-14End: 2021-08-30Updated: 2021-09-17

Phase 4

Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT

Not yet recruitingNCT07762755

China National Center for Cardiovascular DiseasesCoronary Artery Disease, Coronary Atherosclerosis, Hyperlipidaemia +1

Start: 2026-08-01End: 2029-12-31Target: 100Updated: 2026-08-13

Related Papers

Matrix metalloproteinase-9 is associated with CX3CL1 on tau and amyloid biomarker pathways in APOE4 carriers.

2026-09-13

Distinct Roles of MMP‐9 and CX3CL1 on ptau217 and β‐Amyloid Levels in <i>APOE4</i> Carriers versus Noncarriers

Alzheimer s & Dementia2025-12-01

Impact of icosapent ethyl on CSF NULISA vascular, metabolic, and AD biomarkers in cognitively unimpaired Veterans at risk for dementia

Alzheimer s & Dementia2025-12-01

Assessing the effect of eicosapentaenoic acid (EPA) on CSF levels of matrix metalloproteinases and their inhibitors

Alzheimer s & Dementia2025-12-01

Association between remote Traumatic Brain Injury and AD pathology, vascular injury, and cognitive decline among Veterans and non‐Veterans

Alzheimer s & Dementia2024-12-01

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

iScience2021-08-2628 citations